Table 3.

Summary of the physicochemical analysis results for SB11 and EU/US-ranibizumab

Analysis	Attributes	SB11	EU-ranibizumab	US-ranibizumab
SE-HPLC	%Monomer (%)	99.9–100.0	99.9–100.0	99.8–99.9
	%HMW (%)	0.0–0.1	0.0–0.1	0.1–0.2
CE-SDS (non-reduced)	%Main (%)	99.3–99.4	99.0–99.1	98.8–98.9
CE-SDS (reduced)	%Main1 (%)	42.7–43.0	43.0–43.1	43.0–43.1
	%Main2 (%)	56.5–56.8	56.8–56.9	56.7–56.8
icIEF	pI	8.2	8.2	8.2
	%Acidic (%)	3.1–4.1	3.2–3.9	2.9–3.6
	%Main (%)	93.9–95.3	94.2–95.4	94.5–95.5
	%Basic (%)	1.6–1.9	1.4–1.9	1.4–1.8